Atea Pharmaceuticals, Inc. — Director's Dealing 2020

Oct 30, 2020

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Atea Pharmaceuticals, Inc. (AVIR)
CIK: 0001593899
Period of Report: 2020-10-29

Reporting Person: Hack Andrew A. F. (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series D Convertible Preferred Stock	$		Common Stock (3383190)		Indirect
Series D-1 Convertible Preferred Stock	$		Common Stock (1982469)		Indirect

Footnotes

F1: All series of convertible preferred stock will automatically convert into shares of the Issuer's common stock on a 1-for-1 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date.

F2: Represents shares held directly by Bain Capital Life Sciences Fund II, L.P. ("BCLS II") and BCIP Life Sciences Associates, LP ("BCIPLS") and, together with BCLS II, the "Bain Capital Life Sciences Entities").

F3: Bain Capital Life Sciences Investors, LLC ("BCLSI") (i) is the ultimate general partner of BCLS II, and (ii) governs the investment strategy and decision-making process with respect to investments held by BCIPLS. Dr. Hack is a Managing Director of BCLSI. By virtue of the relationships described in this footnote, Dr. Hack may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. Dr. Hack disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.